Introduction: Pancreatic cancer is recognized as one of the most aggressive neoplasms in oncology, characterized by its silent progression and predominantly late-stage diagnosis. Due to its deep anatomical location and the absence of specific early symptoms, early detection is rare, limiting opportunities for curative treatment. The disease exhibits highly invasive behavior, with rapid local and systemic spread, contributing to its poor prognosis. Therapeutic management is complex, usually requiring a combination of surgery, chemotherapy, and palliative care. In the hospital setting, the management of pancreatic cancer demands specialized resources and entails high healthcare costs, reflecting the severity of the clinical condition and the need for high-complexity interventions. Objective: To evaluate the trends in mortality rates and the average hospitalization costs for patients with malignant pancreatic neoplasms in Brazil between 2020 and 2024. Methods: This is a descriptive, quantitative study using data from the Hospital Information System (SIH/SUS) available through DATASUS. The variables analyzed included year of processing, state unit, type of admission, average AIH cost, and mortality rate. Results: Between 2020 and 2024, the mortality rate for pancreatic neoplasms in Brazil was 20.23%, with the Northern region presenting the highest rate at 24.66%. The Central-West region recorded the lowest mortality rate at 17.85%. Observing the annual trend, a gradual decline was noted, with rates of 21.99% in 2020, 20.61% in 2021, 20.04% in 2022, 19.76% in 2023, and 19.23% in 2024. Regarding the type of admission, emergency hospitalizations had a significantly higher mortality rate (25.09%) compared to elective hospitalizations (10.84%), indicating a worse prognosis for cases diagnosed and treated under emergency conditions. The average hospitalization cost for malignant pancreatic neoplasms in Brazil was R$2,018.37. Regionally, the Central-West region had the lowest average cost per hospitalization, at R$1,889.72, while the Northeast region recorded the highest average cost, at R$2,409.46. Conclusion: Malignant pancreatic neoplasms remain among the deadliest cancer types. In the analysis of mortality, the Northern region stood out negatively with the highest mortality rate among Brazilian regions and the third-highest average hospitalization cost. The Northeast had the highest hospitalization costs and the third-highest mortality rate. However, the Central-West region stood out positively by combining the lowest mortality rate with the lowest average hospitalization cost, indicating a more efficient use of healthcare resources in that area—a model that should be expanded to other regions to achieve better clinical outcomes for patients.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
